Bristol Myers to present research across portfolio, pipeline at ASH Meeting

Bristol Myers Squibb announced the presentation of research across its hematology and cell therapy portfolio and pipeline at the 65th American Society of Hematology Annual Meeting and Exposition, which will take place in San Diego, California from December 9 to 12, 2023. Results from 73 data disclosures across company-sponsored studies will be featured, including 22 oral presentations, showcasing BMS’ commitment to delivering transformative medicines that help more patients living with blood disorders. Key data being presented by Bristol Myers Squibb and its partners at the 2023 ASH Annual Meeting and Exposition include: Cell Therapy: First disclosure of efficacy and safety data from the primary analysis of the Phase 2 TRANSCEND FL study of Breyanzi for the treatment of patients with high-risk relapsed or refractory follicular lymphoma in the second-line setting. Patient-reported outcomes and health-related quality of life data from this study will also be presented. First disclosure of Center for International Blood and Marrow Transplant Research registry data showcasing safety and efficacy of Breyanzi in relapsed or refractory large B-cell lymphoma when used in the real world. Multiple analyses from the Phase 3 KarMMa-3 study evaluating Abecma in patients with triple-class exposed relapsed and refractory multiple myeloma, including final progression-free survival data, interim overall survival data, safety profile characterization and patient-reported outcomes from extended follow-up. Updated safety and efficacy results from the Phase 1 study of GPRC5D CAR T in patients with relapsed or refractory multiple myeloma, including in patients with prior BCMA-directed therapy. Targeted Protein Degradation: First results from the Phase 1/2 CC-92480 MM-002 study evaluating CELMoDTM agent mezigdomide with dexamethasone and daratumumab or elotuzumab in patients with relapsed or refractory multiple myeloma. Updated results from the dose-escalation and dose-expansion components of the Phase 1 CC-220-DLBCL-001 study, evaluating potential first-in-class CELMoD agent golcadomide in combination with R-CHOP in previously untreated diffuse LBCL. Translational data describing a potential mechanism of reversal of T-cell exhaustion by CELMoD agents, highlighting the potential for CELMoD agents to enhance T-cell redirecting therapies. Additional Novel Treatment Modalities: Multiple presentations from the Phase 3 COMMANDS study of Reblozyl in the treatment of anemia in patients with lower-risk myelodysplastic syndromes who are erythropoiesis stimulating agent-naive, including primary analysis data, patient-reported outcomes and mutational analysis. Updated safety and efficacy data for potential best-in-class BET inhibitor BMS-986158 in combination with ruxolitinib or Inrebic in first- and second-line myelofibrosis. Updated safety and efficacy data for subcutaneous 2+1 T-cell engager alnuctamab in heavily pretreated multiple myeloma from the Phase 1 CC-93269-MM-001 study.